Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Taysha Gene Therapies' stock has received an average rating of "Moderate Buy" from eleven research firms, with price target estimates averaging around $9.67.
• Insider Sukumar Nagendran sold 200,000 shares at an average price of $3.23, reducing their ownership by 16.58%.
• Institutional investors own 77.70% of Taysha Gene Therapies, highlighting significant institutional interest in the company.

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $9.6667.

A number of research analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Bank of America assumed coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They set a "buy" rating and a $8.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Robert W. Baird boosted their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an "outperform" rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research report on Wednesday, October 8th.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 3.78% of the stock is currently owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently modified their holdings of the company. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $31,000. ST Germain D J Co. Inc. lifted its holdings in shares of Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company's stock valued at $32,000 after buying an additional 4,333 shares during the period. May Hill Capital LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $37,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock valued at $41,000 after purchasing an additional 10,742 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $5.15 on Wednesday. The company has a market cap of $1.40 billion, a P/E ratio of -15.15 and a beta of 0.99. The stock has a fifty day moving average price of $3.56 and a 200 day moving average price of $2.76. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.48 and a quick ratio of 12.48. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $5.51.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The business had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. On average, research analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.